skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Executive Summary

The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.




The 55th annual day celebrations of the 1,000-plus member strong Indian Drug Manufacturers’ Association (IDMA) heard both veiled and direct references to uncertainties around the emergence of a new protectionist regime with US President Donald Trump taking charge, and how several other markets such as Japan and Australia could represent significant opportunities for Indian firms.


Sudhanshu Pandey, joint secretary at India’s Department of Commerce, referred to “rising voices of protectionism” from different parts of the world, but noted that the world had become “more connected, interdependent” making it “next to impossible to reverse the clock” in the foreseeable future.


“Interdependence will only grow and this is going to throw up opportunities for all players,” Pandey predicted at the IDMA event on Jan. 21, noting how Indian generic firms had played a pivotal role in promoting healthcare globally.


Pandey made no direct reference to the US president’s recent views, but Trump’s statements on the need to get “our drug industry back,” and that supplies are not made in the US to a large extent, have triggered some concern in India.


“The biggest issue for Indian companies could be on account of his stance on outsourcing and potential imposition of heavy taxes on ingredients/drugs coming into the US, or a crackdown on overseas manufacturing,” HDFC Securities said in a report dated Jan. 23.


The report also added that US pharma companies that have built overseas supply chains will be “especially wary” of Trump’s threat to impose an import tax on items manufactured abroad.


Challenges, Universal Healthcare


KPMG partner and global head of life sciences, Chris Stirling, in his keynote address at the IDMA event, noted that challenges faced by pharmaceutical companies having to navigate healthcare around the world were somewhat like cricketers having to adapt to different conditions in different countries. (Stirling’s nephew, Sam Billings, is on the English cricket side, he mentioned.)


“As we heard from Mr. Trump, there are difficulties ahead and no one quite knows what’s going to happen with his repeal and replace legislation, which he’s determined to push through.”


He noted that the key question for the world is how to get affordable universal healthcare in every country; KPMG is working with the government of Bahamas and certain provinces in China in this area.


He also referred to one of KPMG's biggest projects concerning New York state that has a budget of $60bn for Medicaid. KPMG has been commissioned by the New York state commissioner to move that spend from being fee-for-service to some kind of outcomes-based payment.


“As we heard from Mr. Trump, there are difficulties ahead and no one quite knows what’s going to happen with his repeal and replace legislation, which he’s determined to push through.” – Chris Stirling, KPMG


“He [the commissioner] wants around 80% to be outcomes-based in five years and also reduce avoidable hospital stays by 25%; this is a massive change for the US and something that was unimaginable only a few years ago," Stirling observed.


Competitiveness, Other Markets


While the US was India’s top destination for pharmaceuticals and fine chemicals in 2014-15 with exports of close to $5bn, joint secretary Pandey highlighted prospects in other markets as well.


India was among the leading suppliers of drugs to the US and the only “so-called low cost economy” in the top five, and Pandey noted how a significant part of US pharmaceutical imports came from “high cost economies” like Ireland, Germany and Switzerland. He believes the Indian industry’s “competitiveness” could help expand its share in the US.


“Therein lies the opportunity for all of you. And I’m discounting the outbound foreign investment from the Indian pharma industry,” he said, adding that Indian firms had invested in excess of an estimated $4bn in the US over the last few years.


Pandey also referred to opportunities in other countries like Japan and Australia, which have had a low share of generics and are now scaling up in this sector.


“With healthcare costs becoming almost unsustainable, both countries have planned to increase the share of generics substantially,” Pandey noted; Europe too is expected to up its share of generics as pressures rise. Generic drugs account for 89% of prescriptions dispensed in the US, bringing $227bn in savings in 2015, as per a report compiled by the QuintilesIMS Institute on behalf of the US Generic Pharmaceutical Association.


Indian pharmaceutical exports to Japan and Australia respectively were just $141m and $205m in 2014-15, according to data from Pharmexcil, the Pharmaceutical Export Promotion Council of India.


There was also a reference to potential opportunities opening up in Switzerland for the supply of ayurvedic products, such as herbal-based medicines. Switzerland had previously voted to add a new article to its constitution for the recognition of complementary and alternative medicine (CAM), making it the first Western nation to implement the integration of CAM in its public health system.


Quality Benchmarks


Meanwhile, Pankaj Patel, chairman and managing director of Zydus Cadila, reflected on the journey of the Indian industry and sought “stability and predictability” in the Indian government’s policies, along with a consultative approach to facilitate further industry growth.


Patel specified the need to promote “Brand India”, while also creating new quality benchmarks. “Every needy person in the world has benefited from medicines in India. However, we haven’t created enough noise or awareness on the support provided.”


However, he acknowledged the challenge faced by industry around quality issues and sought that new benchmarks be set. “It’s not important to be big to be a quality-conscious company,” Patel maintained.


K L Sharma, joint secretary at India’s Ministry of Health and Family Welfare referred to, among a host of other regulatory tweaks in the works, plans for upgrading GMP (good manufacturing practice) requirements in the country, but gave no specifics. Sharma also referred to how quality, at times not necessarily based on facts but “based on perception”, is taken as an “alibi” for protectionism.


Find more content on US election here.



Read also

  • Biomedtracker

    Coming Soon....Early Phase Outlook Report 2017

    08 Feb 2017

    In this report, we cover catalysts from 36 drugs, devices and diagnostics expected to occur in early 2017.

    Topics Drug approval Drug review

  • Scrip

    Pharma's Orphan Drug Activity Infographic

    27 Feb 2017

    More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases. Effective orphan drug legislation and incentivization programs introduced gradually around the world since the 1980s mean rare diseases are no longer a rare sighting in the pharma industry pipeline, as this infographic illustrates.

    Topics Rare Disease

  • Scrip

    eTheRNA CEO outlines development plan in cancer RNA space

    Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: